ENA Respiratory backs INNA-051 for asthma
2026-09-02
Money moves faster than medicine here. A$2.98 million from Biointelect Venturer has locked ENA Respiratory onto a clear path: run a first-in-patients study of its INNA-051 nasal spray in people living with asthma and prove the biology can matter in real disease.
The bet is simple, though the science is not. INNA-051 is designed to act on innate immune receptors in the upper airway, aiming to prime antiviral defenses before pathogens take hold, a strategy rooted in pattern recognition receptor biology and mucosal immunology rather than symptom relief alone. ENA Respiratory already tested the agent in healthy volunteers and in viral challenge models, building a safety and pharmacodynamic profile that suggests the spray can activate local immune pathways without tipping into harmful systemic inflammation.
Asthma care, dominated by inhaled corticosteroids and bronchodilators, has barely touched this upstream innate layer, and that gap is exactly the commercial and clinical opening this program wants to leverage. The Biointelect Venturer capital is earmarked for the trial itself, regulatory engagement, and biomarker-heavy readouts that can link nasal innate immune activation to exacerbation risk, giving investors and clinicians the kind of closed-loop data that can justify a broader development push or, if the signal falls flat, redraw the risk map for host-directed respiratory therapies.
Loading...
